The infamous and ingenious Ho Chi Minh Trail - Cameron Paterson
View full lesson: http://ed.ted.com/lessons/the-infamous-and-ingenious-ho-chi-minh-trail-cameron-paterson The Ho Chi Minh Trail not only connected North and ...

By: TEDEducation

See the rest here:
The infamous and ingenious Ho Chi Minh Trail - Cameron Paterson - Video

Recommendation and review posted by Bethany Smith

FIVE POINTS, Calif., March 17, 2013 /PRNewswire/ -- S&W Seed Company (SANW) today announced that it has agreedtopurchase 100% ofSeed Genetics InternationalPty Ltd("SGI"), subject to due diligence and other customary conditions.The combination of S&W with Adelaide, Australia-based SGI will create the world 's largest non-dormant alfalfa seed company. The transaction, which is valued at approximately $16 million, is scheduled to close in early April 2013 and is expected to be immediately accretive to S&W's earnings.

Mark Grewal, president and chief executive officer of S&W Seed Company, commented, "This pact creates a powerhouse that will be unrivaled in its ability to breed and produce non-dormant alfalfa seed all year round.SGI has a tremendous base of contracted growers, very strong customer relationships, andunique genetics.The sales channels that S&W and SGI sell into are highly complementary,with very little overlap in customers. This move considerably strengthens our reach into Argentina and the rest of Latin America."

Grewal added, "I also want to stress the 'people factor.'S&W is gaining a highly competitive team of veteran seedsmen whom we know well and highly respect. We look forward to collaboration with them in all areas. By putting growers first, SGI's breeding program, initiated by Dr. Ross Downes and now continued by David Pengelly, has created grower-focused varieties that produce more seed per acre for the seed farmer than any other varieties in Australia, adding to seed farmer profits and potentially lowering cost of seed for S&W. We have the opportunity to merge David's work with that of S&W's own VP of Genetics and Breeding, Dan Gardner and our emeritus breeder,Bob Sheesley, who himself did pioneering work in salt tolerance and seed yield."

S&W is paying a purchase price ofapproximately $16million, over half of which consists of 865,000 shares S&W Common Stock and will result in SGI's owners becoming significant shareholders of S&W. The remaining considerationconsists of $5million in cash and$3million in the form of athree-yearpromissory note.Based on unaudited information, SGI hadrevenues of approximately AUD $18million for the fiscal year ended June 30, 2012 andhadpre-tax income of$1.6 million. SGI's assets consist primarily of accounts receivable, inventory, a tenured grower base and intellectual property, such as genetics.S&W intends to file audited financial resultsofSGIno later than 74 daysfrom closing,in compliance with SEC guidelines.

SGIcontrols approximately17,000 acres of irrigated alfalfa seed production under contract, and has first call on another 12,000acres of non-irrigated land that is rain dependent and has intermittent production. Australian seed yields per acre, even on irrigated fields, typically are materially lower than S&W's California yields and production costs are also materially lower.In 2013, SGIcontracted for alfalfa seed production with approximately 140contractfarmersin Southern Australia, all for SGI's proprietary varieties.In fiscal 2012, SGI's growers producedapproximately 5.5 million pounds, concluding a growing season that suffered from the impact of highly adverse weather conditions. The 2013 harvest is currently ongoing, but based on initial estimates, SGI managementis estimating that it will have approximately 8million pounds of alfalfa seed available for sale when the harvest concludes in late April 2013. Actual production could vary materially in either direction from estimates, due to unforeseen weather events and other factors.

SGIsells intointernational markets, includingthe Middle East and Africa (MENA), South America, and Southern Europe with the majority of the company's sales concentrated in the April through September time frame.

SGI was founded in 2002, with the goal of commercializing a seed breeding breakthrough by Dr. Ross Downes. Working with alfalfa in the mid 1990's, Dr. Downes had identified a particular trait that resulted in dramatically increased seed yields, even with less than optimum pollinator activity. The intellectual property stemming from Dr. Downes' pioneering work, which has been protected under international law and the Australian Plant Breeders Rights Act, became the cornerstone for over a decade of development by SGI's David Pengelly. SGI has developed well known proprietary varieties, such asSuperSonic, SuperNova, SuperStar, SuperCharge, SuperAurora, SuperSequal and SuperSiriver. Starting in 2002, the varieties developed by SGI quickly attracted a grower base that by 2012 enabled SGIto exceed 60%of Australian alfalfa seed production.SGI'salfalfa seed varieties are bred to resist disease, have tolerance to salt, create persistence in the field, and produce high seed yields in Australian production.The company also has a number of developments within its breeding program pertaining to dormant alfalfa varieties, tropical alfalfa seed varieties, and ease of pollination.

SGI, like S&W, considers the goodwill of its seed grower base to be of premier importance. SGI's contracts with seedfarmers under long term contracts that typically have initial terms of six years, extendable to ten years. To manage risk for itself and its growers, seed pricing is not fixed by contract, but instead based upon pooled production which is sold over an entire season, with a view to optimizing the prices realized. Due to its Southern Hemisphere location,SGIharvests seed in March through April, which is counter cyclical to S&W's July through October production in the Northern Hemisphere. The combined company will have the competitive advantages of year round production, which extends to all areas of the alfalfa seed business, including sales, inventory management and cash collection cycles.

Mark Harvey,Directorof Seed Genetics International, commented, "First, my thanks to S&W's Chairman, Grover Wickersham, and S&W's CFO, Matt Szot, for their long visits to Australia and their patience in negotiating over the last half year. While this is obviously a big move for us, the directors and management of SGI are trulyexcited about the advantages of a combined S&W/SGI and we want the challenge of continuing to build on what the four partners started."

Mr. Harvey expanded, "For our Australian growers, this means we willbeexpanding production under the umbrella of a public company with a strong balance sheet and financial resources. We also gain access to S&W's proven proprietary genetics. We look forward to collaborating with S&W's well respected breeder, Dan Gardner, who is well known by our own David Pengelly and Ross Downes. When we learned last year that Dan and our tough and respected sales and marketing competitor from IVS, Fred Fabre, had both joined S&W, it piqued ourinterest."

Read more:
S&W Seed Company To Acquire Seed Genetics International

Recommendation and review posted by Bethany Smith

Professor Dinggang Li, M.D. - gene therapy, Gendicine
Professor Dinggang Li md gene therapy Gendicine. Uploaded by Danni ElKher on Mar 14 2013. Itroduction of the hospitals of Phoenix Hosiptal Group Beijing Health Palace Hospital and Beijing Yanhua Phoenix Hospital with Professor Dinggang Li md in front Gene therapy also known as Gendicine has been proven to be very useful in the fight against cancer Scandinavian patients wwwkirurgirejserdk. Plu Mb 69.

By: Danni El-Kher

See the rest here:
Professor Dinggang Li, M.D. - gene therapy, Gendicine - Video

Recommendation and review posted by Bethany Smith

Patients can turn off an experimental treatment if side effects get too bad.

A unique new cancer treatment uses gene therapy to induce a cancer-fighting immune response whose intensity can then be controlled with a pill. The combination could help tailor treatment to a patients individual response.

The treatment uses the bodys own cells or tumor cells to produce extra copies of a naturally occurring hormone-like molecule called IL-12, which regulates anticancer immune responses. Last week, Ziopharm Oncology announced a clinical study of the treatment for patients with breast cancer. The company is already testing it in patients with melanoma.

Many researchers have explored techniques that rev up the natural response the body uses to detect and attack cancerous cells (see, for example, Engineering Better Immune Cells and Priming the Body to Tackle Cancer). But controlling the killer cells of the immune system can sometimes be a challenge, as researchers found in the 1990s when cancer patients who were given IL-12 in a clinical trial died from toxic side effects.

IL-12 is a very potent [immune system regulator] and can generate a lot of side effects, says Per Basse, a physician-scientist at the University of Pittsburgh School of Medicine, who studies immune cells and their ability to fight cancer. As a clinician, I would like to be able to dial it up and down so that if it all starts to look not so good, you can stop the process, he says.

To avoid the dangerous side of the molecule, Ziopharms system is designed to control IL-12 with a combined genetic and pharmaceutical switch. A virus is injected into the tumor to deliver the gene for IL-12. The gene starts out in off mode, so it doesnt actually produce any IL-12. To activate the gene, a patient has to take a pill that delivers another molecule. The advantage is that any patient who starts to experience nasty side effects from the IL-12 can stop taking the pill. If things go awry, you have an escape valve, says Ziopharms CEO, Jonathan Lewis.

The key to the inducible system is a version of the receptor that controls molting in arthropods (insects, spiders, and crustaceans), modified so that it determines whether the IL-12 gene is on. The gene for that receptor, which is also delivered into the body by a virus, is always on, but its protein product and thus IL-12 expression is activated by the pill. Ziopharm licensed the control system from Intrexon for use in its oncology treatment.

The inducibility is a great idea, but the trick is getting something that you can get into the tumor, says Ralph Weichselbaum, a cancer researcher at the University of Chicago, who has worked on a cancer therapy induced by radiation. Currently, Ziopharm injects the gene-toting virus directly into patients tumors, but Lewis says the plan is to inject it into muscles in the future. Muscle cells are extremely good protein production factories, he says.

But even injecting the virus into a single tumor has an effect on other tumorsboth in lab animals and in humans. In animal studies, the tumor that receives the injection will at first get bigger because immune cells are accumulating in response to the IL-12. Then it will get smaller and go away, says Lewis. Tumors that received no injection will do the same thinggrow, then shrink, and then disappear. We are seeing similar things in people, says Lewis.

Eventually, the system could be used to deliver multiple genetic treatments at once, says Lewis. With one injection you could be able to control three or four [cancer-fighting] proteins in different ways.

See the rest here:
A Cancer Gene Therapy Activated by a Pill

Recommendation and review posted by Bethany Smith

TEDMED Great Challenges: The Future of Personalized Medicine
You need Adobe Flash Player to watch this video. Download it from Adobe. TEDMED Great Challenges The Future of Personalized Medicine. Catherine Andrews18 videos. SubscribeSubscribedUnsubscribe 36. Like. Sign in to youtube. Sign in with your youtube Accountyoutube Google+ Gmail Orkut Picasa or Chrome to like Catherine Andrewss video. Sign in. I dislike this. Sign in to youtube. Sign in with your youtube Accountyoutube Google+ Gmail Orkut Picasa or Chrome to dislike Catherine Andrewss ...

By: Catherine Andrews

Read more:
TEDMED Great Challenges: The Future of Personalized Medicine - Video

Recommendation and review posted by sam

Smallpox was eradicated completely in 1980. The only known stocks of the virus that causes smallpox are in carefully guarded laboratories in the U.S. and Russia. Nevertheless, the U.S. government is spending nearly $500 million for about two million doses of smallpox vaccine, according to a recent article in the New York Times.

Does this make sense? Well, yes and no. No one knows for sure whether there are unreported stocks of the virus somewhere, and if there are, whether they might fall into the wrong hands. Apparently the U.S. government thinks that it would be prudent to have a stock of smallpox vaccine on hand, just in case the smallpox virus is used someday in a bioterrorism attack.

Only time will tell whether stockpiling smallpox vaccine will prove to be a $500 million waste of money or a lifesaver. But while you’re considering whether you think it’s a good idea, consider this; if there is an outbreak of smallpox some day, who will be able to get the vaccine? Two million doses wouldn’t cover even a quarter of the population of New York City alone. How much of this vaccine should we be stockpiling?Source:
http://humanbiologyblog.blogspot.com/2013/03/stockpiling-smallpox-vaccine_14.html

Recommendation and review posted by Bethany Smith

Cell Therapy for Myeloma and Lymphoma by Dr Larry Kwak
Dr Larry Kwak, Professor and Chair of the department of Myeloma and Lymphoma at MD Anderson Cancer Center, Houston gave an update on the progress in cell the...

By: TheMedalGroup

The rest is here:
Cell Therapy for Myeloma and Lymphoma by Dr Larry Kwak - Video

Recommendation and review posted by Bethany Smith

Cell Therapy for Allogeneic Stem Cell Transplant by Dr Richard Champlin
Dr Richard Champlin, Professor and Chair of the department of Stem Cell Transplant and Cellular Therapy gave an update on the role of Cell Therapy in improvi...

By: TheMedalGroup

Read more:
Cell Therapy for Allogeneic Stem Cell Transplant by Dr Richard Champlin - Video

Recommendation and review posted by Bethany Smith

STEM CELL Therapy thru Laminine_Part-1(new link)
STEM CELL Therapy thru laminine_part1new link. Uploaded by cabmon0001 on Mar 14 2013. cabmon 0001.

By: cabmon0001

Original post:
STEM CELL Therapy thru Laminine_Part-1(new link) - Video

Recommendation and review posted by Bethany Smith

STEM CELL Therapy thru Laminine_Part-2(new link)
STEM CELL Therapy thru laminine_part2new link. Uploaded by cabmon0001 on Mar 14 2013. cabmon 0001.

By: cabmon0001

Read the original:
STEM CELL Therapy thru Laminine_Part-2(new link) - Video

Recommendation and review posted by Bethany Smith

Gene breakthrough welcomed by Daisy's Eye Cancer Fund

10:20am Saturday 16th March 2013 in News

AN Oxford-based charity supporting young children suffering eye cancer has welcomed a breakthrough in research.

Abby White, 36, from Iffley, runs Daisys Eye Cancer Fund, which supports families whose children suffer retinoblastoma. Retinoblastoma is a rapidly developing eye cancer affecting about 45 babies a year in the UK under the age of five. Ms White inherited the condition from her father and set up the charity in 2004.

The funds medical director Dr Brenda Gallie, based in Toronto, Canada, has published new findings in Lancet Oncology, which are set to change clinical practice.

She said research revealed that a single gene had been identified as being responsible for a new type of retinoblastoma.

Dr Gallie added: The common type of retinoblastoma can be inherited, so the childs other eye and infant relatives are at risk to develop cancer.

When we remove the eye of a very young baby with a large tumour and discover it is the new oncogene-driven retinoblastoma, there is zero risk for the other eye or infant blood relatives.

Ms White said: Im very pleased with this breakthrough.

Children are diagnosed earliest when parents notice the eye has a white, instead of black, pupil in flash photos or dim light.

Read more here:
Gene breakthrough welcomed by Daisy's Eye Cancer Fund

Recommendation and review posted by Bethany Smith

Mar. 14, 2013 For deer mice living in the Nebraska Sandhills, color can be the difference between life and death.

When the dark-coated mice first colonized the region, they stood out starkly against the light-colored, sandy soil, making them easy prey for predators. Over the next 8,000 years, however, the mice evolved a system of camouflage, with lighter coats, changes in the stripe on their tails, and changes in body pigment that allowed them to blend into their habitat.

Now Harvard researchers are using their example to answer one of the fundamental questions about evolution. Is it a process marked by large leaps -- single mutations that result in dramatic changes in an organism -- or is it the result of many smaller changes that accumulate over time?

As described in a March 15 paper in the journal Science, a team of researchers, including former Harvard postdoctoral fellow Catherine Linnen, now an assistant professor at the University of Kentucky, and led by Hopi Hoekstra, Harvard professor of organismic and evolutionary biology and molecular and cellular biology, were able to show that the changes in mouse coat color were the result not of a single mutation but of at least nine mutations within a single gene.

"The findings demonstrate how the cumulative effect of natural selection, acting on many small genetic changes, can produce rapid and dramatic change," said Linnen, the first author of the paper. "This helps us to understand, from a genetic perspective, the uncanny fit between so many organisms and their environments. By acting on many small changes, rather than a handful of large ones, natural selection can produce very finely honed adaptations."

Surprisingly, Hoekstra said, that honing occurred in a single gene.

The role of this gene, called agouti, in camouflage was first discovered by Linnen, Hoekstra, and colleagues in 2009, and it is responsible for changes in pigmentation in the coats of many animals. Every domesticated black cat, for example, has a DNA deletion in the gene.

What surprised Hoekstra and her team, however, wasn't that the gene was involved, but that each of the nine mutations were tied to a unique change in the animal's coats, that all the new mutations led to more camouflaging color, and that the mutations occurred in a relatively short, 8,000-year timeframe.

"Essentially, it seems as though these mutations -- each of which makes the mouse a little lighter and more camouflaged -- have accumulated over time," Hoekstra said.

Focusing on these mutations, researchers then examined the DNA of natural populations of the mice to determine whether the mutations are actually beneficial.

Go here to see the original:
One gene , many mutations: Key that controls coat color in mice evolved nine times

Recommendation and review posted by Bethany Smith

Johnathan Blair / National Geographic

A museum worker inspects a replica of a woolly mammoth, a species that went extinct 3,000 to 10,000 years ago. In March 2012, scientists in Russia and South Korea announced a partnership to try to clone the mammoth and generate a living specimen.

By Alan Boyle, Science Editor, NBC News

If scientists can use genetic engineering to bring back the woolly mammoth, should they do it? How about the passenger pigeon? Or the western black rhino? Do we humans have a responsibility to restore at least some of the species that our ancestors wiped out? And if we bring them back, will they really be the same?

Such questions are the focus of TEDxDeExtinction, a public forum that's being presented on Friday from 8 a.m. to 5 p.m. ET at National Geographic's Washington headquarters. You can watch the whole thing online via LivestreamTEDx and National Geographic's De-Extinction website, which also has loads of articles and resources on the issue. The event has been organized by Revive & Restore, a nonprofit clearinghouse for worldwide de-extinction work that's under the aegis of the Long Now Foundation in San Francisco.

"De-extinction"? What's that?

"It's using new technologies like cloning and genome sequencing to reconstruct a species that went extinct," science writer Carl Zimmer explained. Zimmer's talk at Friday's TEDx event will help set the scene for the de-extinction debate, and he's also written a cover story on the topic for National Geographic's April issue.

National Geographic

National Geographic's cover story for the April issue focuses on the prospects of reviving ancient species.

De-extinction has been in the works for more than a decade, basically ever since Dolly the Sheep demonstrated in 1996 that mammals could be cloned from cells in a lab dish. Spanish and French scientists worked for years on an effort to bring the Pyrenean ibex back from extinction, by cloning cells that had been preserved from the last known animal of the species. They succeeded only in producing a deformed kid that died 10 minutes after birth.

Read the original post:
Should we revive extinct species? Watch experts debate de-extinction

Recommendation and review posted by Bethany Smith

Johnathan Blair / National Geographic

A museum worker inspects a replica of a woolly mammoth, a species that went extinct 3,000 to 10,000 years ago. In March 2012, scientists in Russia and South Korea announced a partnership to try to clone the mammoth and generate a living specimen.

By Alan Boyle, Science Editor, NBC News

If scientists can use genetic engineering to bring back the woolly mammoth, should they do it? How about the passenger pigeon? Or the western black rhino? Do we humans have a responsibility to restore at least some of the species that our ancestors wiped out? And if we bring them back, will they really be the same?

Such questions are the focus of TEDxDeExtinction, a public forum that's being presented on Friday from 8 a.m. to 5 p.m. ET at National Geographic's Washington headquarters. You can watch the whole thing online via LivestreamTEDx and National Geographic's De-Extinction website, which also has loads of articles and resources on the issue. The event has been organized by Revive & Restore, a nonprofit clearinghouse for worldwide de-extinction work that's under the aegis of the Long Now Foundation in San Francisco.

"De-extinction"? What's that?

"It's using new technologies like cloning and genome sequencing to reconstruct a species that went extinct," science writer Carl Zimmer explained. Zimmer's talk at Friday's TEDx event will help set the scene for the de-extinction debate, and he's also written a cover story on the topic for National Geographic's April issue.

National Geographic

National Geographic's cover story for the April issue focuses on the prospects of reviving ancient species.

De-extinction has been in the works for more than a decade, basically ever since Dolly the Sheep demonstrated in 1996 that mammals could be cloned from cells in a lab dish. Spanish and French scientists worked for years on an effort to bring the Pyrenean ibex back from extinction, by cloning cells that had been preserved from the last known animal of the species. They succeeded only in producing a deformed kid that died 10 minutes after birth.

Originally posted here:
Should we resurrect extinct species? Watch experts debate de-extinction

Recommendation and review posted by Bethany Smith

Johnathan Blair / National Geographic

A museum worker inspects a replica of a woolly mammoth, a species that went extinct 3,000 to 10,000 years ago. In March 2012, scientists in Russia and South Korea announced a partnership to try to clone the mammoth and generate a living specimen.

By Alan Boyle, Science Editor, NBC News

If scientists can use genetic engineering to bring back the woolly mammoth, should they do it? How about the passenger pigeon? Or the western black rhino? Do we humans have a responsibility to restore at least some of the species that our ancestors wiped out? And if we bring them back, will they really be the same?

Such questions are the focus of TEDxDeExtinction, a public forum that's being presented on Friday from 8 a.m. to 5 p.m. ET at National Geographic's Washington headquarters. You can watch the whole thing online via LivestreamTEDx and National Geographic's De-Extinction website, which also has loads of articles and resources on the issue. The event has been organized by Revive & Restore, a nonprofit clearinghouse for worldwide de-extinction work that's under the aegis of the Long Now Foundation in San Francisco.

"De-extinction"? What's that?

"It's using new technologies like cloning and genome sequencing to reconstruct a species that went extinct," science writer Carl Zimmer explained. Zimmer's talk at Friday's TEDx event will help set the scene for the de-extinction debate, and he's also written a cover story on the topic for National Geographic's April issue.

National Geographic

National Geographic's cover story for the April issue focuses on the prospects of reviving ancient species.

De-extinction has been in the works for more than a decade, basically ever since Dolly the Sheep demonstrated in 1996 that mammals could be cloned from cells in a lab dish. Spanish and French scientists worked for years on an effort to bring the Pyrenean ibex back from extinction, by cloning cells that had been preserved from the last known animal of the species. They succeeded only in producing a deformed kid that died 10 minutes after birth.

Read more:
Follow the big debate over de-extinction

Recommendation and review posted by Bethany Smith

So, you want to know more about the genes that make you what you are? Or, maybe youre interested in knowing what your potential disease vulnerability is by getting your genome sequenced? Well, you may want to think twice, or maybe three times before taking the dive. Costing fromseveral hundred to thousands ofdollars, theyre now sold over the Internet, and there are plans to sell them in drugstores. Some tests claim to provide personal nutrition advice based on your genetic profile. Usually all you have to do is rub a swab inside your cheek and mail it to the company, which will scan your DNA, looking for mutations and variations that suggest increased risk, and then send you the results.

Home tests have not been reviewed by the FDA or any other agency, unlike most physician-ordered genetic tests or other kinds of at-home medical tests. And, theres no data to indicate the take home tests are even accurate to begin with. In addition, the FDA has advised some home test makers to submit factual test based results, given that some companies are claiming to be able to devise health care plans based on an individuals personal genetic results, which can start to be borderline legal.

One problem is the overblown claims made in much of the marketing material. In most cases, theres no research showing that the results of the tests can help people prevent disease or lead to better treatment or longer lives. Government testing in 2010 showed that for every genetic test they evaluated, the results varied by which company was supplying the swabs, and each companies lab. In the end, the government indicated theres no evidence that any particular test is accurate or preferred, or even if the results are accurate, that andrecommendations made by the companies are true, accurate, or useful.

Moreover, no one (or even two) genes necessarily stand alone in the functioning of the human body,let alonein disease issues. It is the passage of time, the physical environment, the social environment, and a host of individual experiences and interactions that are likely to be as involved as any single gene.

Even if you have a gene or two that makes you susceptible to sugar diabetes, for example, by controlling your weight and exercising, those genes may never be activated. Alternately, you might not have a genetic susceptibility, but by having a dangerous lifestyle, you could still develop the disease.

dditionally, and this is true of more complex diseases, you might not ever develop a sickness because of other issues that develop through the course of a lifetime. This could mean anything from at what age a disease might begin; is it 50 for you, and 60 for someone else,and not until 80 for most people? And lets say a disease normally wouldnt show up until 80 years of age. What if you found out about a genetic predisposition for such a disease, but you only live until 77 anyway? You could have had a lifetime of worry and concern for nothing.

Although the science of genetic testing is progressing rapidly, and holds vast potential on an individual basis, its too early in the game to rely on, and especially act on specific genetic tests you may take. This is especially true for any at home tests.

In some circumstances, its reasonable to consider genetic testing, when its done in conjunction with a health-care professional knowledgeable in genetic medicine and by a specialized lab. There are a few cases in which genetic testing in a specialized lab could be warranted, and Ive spelled those out below:

Breast cancer: About 2 percent of women have a family history strong enough to warrant testing. If the results are positive, you should have frequent mammograms and other testing (such as MRIs), and may even decide to have prophylactic surgery.

Colon cancer: If you have a strong family history of this cancer, you need frequent colonoscopies to find and remove polyps. Genetic testing can be helpful in determining if you need even more frequent colonoscopies.

See the original post:
BY GEORGE: Is Genetic Testing For You?

Recommendation and review posted by Bethany Smith

DNA "S RECAP ON HIS BATTLE WITH K - SHINE
AFTER URL "S EVENT " UNFINISHED BUSINESS " DNA GIVES THE FANS HIS RECAP ON HIS HIGHLY ANTICIPATED BATTLE WITH K SHINE ... LEAVE YA COMMENTS AND GIVE YOUR FEE...

By: Eric St John

Visit link:
DNA "S RECAP ON HIS BATTLE WITH K - SHINE - Video

Recommendation and review posted by Bethany Smith

Working backward to solve problems - Maurice Ashley
View full lesson: http://ed.ted.com/lessons/working-backward-to-solve-problems-maurice-ashley Imagine where you want to be someday. Now, how did you get ther...

By: TEDEducation

See the rest here:
Working backward to solve problems - Maurice Ashley - Video

Recommendation and review posted by Bethany Smith

Focus on Karla Neugebauer - part one: RNA processing
EMBO Member Karla Neugebauer, Senior Group Leader at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, talks to Barbara Pauly about...

By: EMBOcomm

See the article here:
Focus on Karla Neugebauer - part one: RNA processing - Video

Recommendation and review posted by Bethany Smith

How Old Is the Human Race?
How long have humans been walking the planet? Turns out, the answer is in our genes! Trace explains. Read More: "African American Man #39;s DNA Dates Back 338,00...

By: DNewsChannel

Read this article:
How Old Is the Human Race? - Video

Recommendation and review posted by Bethany Smith

It #39;s Genetics Story Time, with your host, Sofiarune
http://theunsilencedscience.blogspot.com/ http://theunsilencedscience.blogspot.com/2012/09/genes-dealt-made-asians-svelte.html Bibliography Beaver and Chavia...

By: n00ffensebut

Read the original:
It's Genetics Story Time, with your host, Sofiarune - Video

Recommendation and review posted by Bethany Smith

LASER GENETICS: MINI-ND5-SUBZERO
LASER GENETICS MININD5SUBZERO. gamooutdoor89 videos. SubscribeSubscribedUnsubscribe 2035. 96 views. Like 5 Dislike 0. Like ... Laser Genetics ND3 and ND7 Series laser products SHOT Show 2010by outdoorchannel 23295 views; 136. Watch Later bsa #39;s green laserlong distance lightby outdoorchannel 17837 views; 046. Watch Later LASER GENETICS ND1 SUBZEROby gamooutdoor 64 views; 032. Watch Later wwwlasergeneticseu ND3 ND5 nightvisionby Rok Q 9577 views; 059 ...

By: GamoOutdoor

See the original post here:
LASER GENETICS: MINI-ND5-SUBZERO - Video

Recommendation and review posted by Bethany Smith

Researchers Aim Unlock Genetic Data Goldmine
Researchers in the San Francisco Bay area believe genetic tests will help them find the best ways to treat and potentially prevent diseases such as Alzheimer...

By: PBSNewsHour

See the original post here:
Researchers Aim Unlock Genetic Data Goldmine - Video

Recommendation and review posted by Bethany Smith

Coursera Genetics Evolution 2013 hangout
Coursera Genetics Evolution 2013 hangout. Mohamed Noor43 videos. SubscribeSubscribedUnsubscribe 163. Like .... Watch Later introastro Hangout 4by Justin Ronen middot; 3443. Watch Later Free College ClassesMooc #39;s Coursera Udacity edx Khan codeacademyby babasuter 1364 views middot; 2501. Watch Later introastro Hangout6by Justin Ronen middot; 4913. Watch Later Coursera Genetics Evolution meetupby Mohamed Noor middot; 12815. Watch Later Thinking Unenslaved June 24 2012by Synthaetica middot; 500 ...

By: Mohamed Noor

Read the original here:
Coursera Genetics

Recommendation and review posted by Bethany Smith

67 WALL STREET, New York - March 15, 2013 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Cardiac - Health Care - Affordable Care Act

Companies include: Atossa Genetics, Inc. (ATOS) and many more.

In the following excerpt from the Medical Devices Report, the CEO of Atossa Genetics, Inc. (ATOS) discusses company strategy and the outlook for this vital industry.

TWST: Let's start with a quick overview of Atossa Genetics and how you view the company at this point?

Dr. Quay: Atossa Genetics, the Breast Health Company, was founded in 2009. Our focus is on four laboratory tests, including two under development, that provide information to clinicians and patients about all aspects of breast health as well as a planned treatment program for early cancer using an intraductal microcatheter system.

TWST: Explain for us the mechanics of breast cancer diagnosis and detection through NAF? What are the typical fields of inquiry?

Dr. Quay: I think to frame that question, it's good to review where we are currently in the medical paradigm around breast cancer. The imaging techniques we use, mammography, ultrasound and MRI, are all based on using physics to measure changes in the breast and especially to identify cancer at a stage where it is big enough to be seen. That takes about one billion cells all in one spot.

At that point, the medical system's paradigm is do what some doctors call "cut, burn and poison," where a patient has a surgeon remove either the lump of cancer or the entire breast, a radiation therapist then passes X-rays into either the breast or the entire chest wall, and then an oncologist uses intravenous and oral chemotherapy to kill any cells that may have escaped the surgeon's knife or the X-rays and gotten into the body. That is the current paradigm.

It's unfortunate in that it doesn't work as well as we all would like it to work. We still have 235,000 women a year getting breast cancer. If you compare that to the situation with cervical cancer, where we've had an 80% reduction in cervical cancer...

Link:
Wall Street Transcript Interview with Steven Quay, CEO of Atossa Genetics , Inc. (ATOS)

Recommendation and review posted by Bethany Smith